SEARCH:   Advanced

Blood, 15 November 2006, Vol. 108, No. 10, pp. 3302-3304. Prepublished online as a Blood First Edition Paper on August 8, 2006; DOI 10.1182/blood-2006-04-016709. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-016709v1 108/10/3302    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jeha, S. Articles by Pui, C.-H. Search for Related Content PubMed PubMed Citation Articles by Jeha, S. Articles by Pui, C.-H. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 12, 2006 Accepted July 9, 2006 Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia Sima Jeha*, Frederick Behm, Deqing Pei, John T Sandlund, Raul C Ribeiro, Bassem I Razzouk, Jeffrey E Rubnitz, Nobuko Hijiya, Scott C Howard, Cheng Cheng, and Ching-Hon Pui St Jude Children's Hospital Research Hospital, Memphis, Tennessee, USA * Corresponding author; email: sima.jeha{at}stjude.org. CD20 expression is associated with inferior survival in adults with ALL. We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated on three consecutive St. Jude Total Therapy studies. CD20 expression (>20%) was found in 169 patients (48%), and was more frequent in patients between 1 and 10 years of age than in those younger than 1 or older than 10 years (p=0.001). None of 14 patients with MLL-AF4 expressed CD20. There was no association between CD20 expression and E2A-PBX, TEL-AML1, ploidy, WBC at diagnosis, or gender. In contrast to the experience in adult ALL, our patients with CD20 expression tended to have a better treatment outcome than those without the expression: 5-year event free survival 84% ± 2.9% versus 78% ± 3.1% (p=0.08). This data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. A. Thomas, S. O'Brien, J. L. Jorgensen, J. Cortes, S. Faderl, G. Garcia-Manero, S. Verstovsek, C. Koller, S. Pierce, Y. Huh, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia Blood, June 18, 2009; 113(25): 6330 - 6337. [Abstract] [Full Text] [PDF] M. S Rayburg, D. Marmer, J. Mo, R. McMasters, T. Smolarek, B. Lampkin, and J. Perentesis Prevalence and Clinical Characterization of CD20 and CD22 Expression in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 4872 - 4872. [Abstract] M. N. Dworzak, A. Schumich, D. Printz, U. Potschger, Z. Husak, A. Attarbaschi, G. Basso, G. Gaipa, R. Ratei, G. Mann, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy Blood, November 15, 2008; 112(10): 3982 - 3988. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020